Vivos Therapeutics Posts Sales Gain and Smaller Loss, but Cash Position Stays Precarious
The sleep apnoea devices group grew third-quarter sales by almost a quarter on the prior quarter and cut its loss, while Nasdaq signed off on its equity position after an October deal.
17 Nov 2026 · Vivos Therapeutics, Inc. VVOS · Company news
Vivos Therapeutics, a US business selling sleep apnoea devices and related services, has reported a stronger third quarter, with sales of $6.4m for the three months to 30 September 2026. That is 24% above the figure for the preceding quarter.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
or
Company's press release (SEC filing): Vivos Therapeutics, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
More EarningsAll →
Earnings
Prenetics widens H2 EBITDA loss guidance to $30-35M as IM8 spending rises
18 Nov 2026 · Prenetics Global Ltd PRE · Company news
Earnings
newcleo reports Q3 revenue of about €10M and €233.4M cash as PRECURSOR e-core completed
18 Nov 2026 · newcleo plc NWCL · Company news
Earnings
Iridex cuts 2026 revenue guidance to $46-48M after 19% third-quarter sales drop
17 Nov 2026 · Iridex Corp IRIX · Company news
Earnings
Interpace Biosciences Q3 revenue rises 18% to $10.4M on thyroid testing growth
17 Nov 2026 · Interpace Biosciences, Inc. IDXG · Company news
Earnings
Zentek reports C$15.2M six-month profit on impairment reversal; cash rises to C$13.6M
17 Nov 2026 · Zentek Ltd. ZTEKF · Company news
Earnings
Mesoblast reports US$115M first full-year Ryoncil sales and advances four late-stage programmes
17 Nov 2026 · Mesoblast Ltd MESO · Company news